All articlesMedia Stories

Good Morning Britain: Robb Dixon Speaks Out About Post-Finasteride Syndrome

On 11 February 2026, SIDEfxHUB Communications Director Robb Dixon appeared live on ITV's Good Morning Britain to share his experience with…

By Morten SkovPublished Updated

This is coverage by another outlet. We link to it because it reports on PFS, PSSD or PAS — the reporting and any views in it are the publisher's, not ours.

On 11 February 2026, SIDEfxHUB Communications Director Robb Dixon appeared live on ITV’s Good Morning Britain to share his experience with Post-Finasteride Syndrome (PFS). Robb described how his life was changed after taking finasteride for hair loss, developing debilitating side effects that persist ten years after stopping the drug.

The segment, which also featured pharmacist Thorrun Govind, highlighted the Royal Pharmaceutical Society’s warning that buying prescription drugs online is a “ticking time bomb” for public safety. Robb’s testimony brought the reality of PFS into millions of living rooms across the UK.

Massive response

The appearance generated significant awareness and resulted in a wave of people reaching out to SIDEfxHUB after recognising their own symptoms. Many had been suffering in silence, unaware that their condition had a name or that others were affected.

The YouTube video has been viewed thousands of times and the comments section is filled with PFS sufferers sharing their own stories — some dealing with the condition for over eight years.

About SIDEfxHUB

SIDEfxHUB is a UK-registered charity (No. 1203385) dedicated to supporting patients affected by Post-Finasteride Syndrome (PFS), Post-SSRI Sexual Dysfunction (PSSD), and Post-Accutane Syndrome (PAS). If you or someone you know is affected, visit our patient registry or contact us.

If you are in crisis: 116 123 Samaritans (UK) 988 Lifeline (US) Find a helpline

Free live webinar

Get your report filed this weekend

A live walkthrough on Zoom, free to join.

Sign up free

Times shown in UK and US Eastern time.